Skip to main content
Premium Trial:

Request an Annual Quote

MolecularMD Gets CE Mark for CDx Assay Used in Daiichi Sankyo Clinical Trial

NEW YORK (GenomeWeb) – Molecular diagnostics company MolecularMD announced today that it has received CE marking for a custom companion diagnostic it developed for a Daiichi Sankyo clinical trial.

The Phase II trial is testing a cancer therapy in Europe, MolecularMD said. The firm's assay is being used to select patients to participate.

"Identifying the precise subset of patients who may respond to our compound helps to fully assess its potential efficacy and safety profile," Antoine Yver, executive VP and global head of Daiichi Sankyo's oncology R&D, said in a statement.

The deal with Daiichi Sankyo is one of several similar agreements MolecularMD has signed with prominent biopharmaceutical companies, the firm added. "MolecularMD is entirely focused on accelerating development of precision oncology medicines. Our work with Daiichi Sankyo demonstrates our ability to support a wide spectrum of clinical and regulatory strategies," said CEO Dan Snyder in a statement.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.